Escalé-Besa A., Fuster-Casanovas A., Börve A., Yélamos O., Fustà-Novell X., Rafat M.E., Marin-Gomez F.X., Vidal-Alaball J.. Using Artificial Intelligence as a Diagnostic Decision Support Tool in Skin Disease: Protocol for an Observational Prospective Cohort Study. Jmir Research Protocols. 2022; 11(8)DOI:10.2196/37531. PMID:. IF:(Q/D).

Bechman K., Cook E.S., Dand N., Yiu Z.Z.N., Tsakok T., Meynell F., Coker B., Vincent A., Bachelez H., Barbosa I., Brown M.A., Capon F., Contreras C.R., De La Cruz C., Meglio P.D., Gisondi P., Jullien D., Kelly J., Lambert J., Lancelot C., Langan S.M., Mason K.J., McAteer H., Moorhead L., Naldi L., Norton S., Puig L., Spuls P.I., Torres T., Urmston D., Vesty A., Warren R.B., Waweru H., Weinman J., Griffiths C.E.M., Barker J.N., Smith C.H., Galloway J.B., Mahil S.K.. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2)DOI:10.1111/bjd.21042. PMID:35104366. IF:10.300(Q1/1D).

Zachariae C., Mrowietz U., Strodl Andersen J., Puig L.. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4)DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2.500(Q2/5D).

Sánchez-Rodríguez G., Puig L.. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6)DOI:10.1016/j.piel.2021.06.020. PMID:. IF:(Q/D).